Seglitide

Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR2) agonist, and also a competitive antagonist of SSTR14, SSTR25, and SSTR28. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes[1][2][3].

Product Specifications

CAS Number

[81377-02-8]

Product Name Alternative

MK-678; L-363586

UNSPSC

12352209

Target

Somatostatin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/seglitide.html

Purity

99.30

Solubility

10 mM in DMSO

Smiles

O=C([C@@H](NC([C@@H](N(C([C@@H](NC([C@@H](NC([C@@H](NC1=O)CCCCN)=O)C(C)C)=O)CC2=CC=CC=C2)=O)C)C)=O)CC3=CC=C(C=C3)O)N[C@@H]1CC4=CNC5=CC=CC=C45

Molecular Formula

C44H56N8O7

Molecular Weight

808.96

References & Citations

[1]Dimech J, et al. Antagonist effects of seglitide (MK 678) at somatostatin receptors in guinea-pig isolated right atria. Br J Pharmacol. 1993;109 (4) :898-899.|[2]Bhattarai J P, Kaszas A, Park S A, et al. Somatostatin inhibition of gonadotropin-releasing hormone neurons in female and male mice[J]. Endocrinology, 2010, 151 (7) : 3258-3266.|[3]Hartmann J, et al. Blood pressure reduction in hypertensive-diabetic rats by the somatostatin analog MK-678. Life Sci. 1989;45 (3) :267-74.